- Home
- RPTX
as 07-08-2024 1:38pm EST
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company derives maximum revenue from Canada.
| Founded: | 2016 | Country: | Canada |
| Employees: | N/A | City: | SAINT-LAURENT |
| Market Cap: | 150.7M | IPO Year: | 2020 |
| Target Price: | $17.33 | AVG Volume (30 days): | 149.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.10 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.98 - $13.85 | Next Earning Date: | 08-07-2024 |
| Revenue: | $97,859,000 | Revenue Growth: | -28.62% |
| Revenue Growth (this year): | 19.44% | Revenue Growth (next year): | -53.51% |
Stock Insider Trading Activity of Repare Therapeutics Inc. (RPTX)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Forte Steve | RPTX | EVP, CHIEF FINANCIAL OFFICER | Mar 28 '24 | Sell | $4.61 | 789 | $3,637.29 | 44,775 | SEC Form 4 |
| Segal Lloyd Mitchell | RPTX | PRESIDENT AND CEO | Mar 28 '24 | Sell | $4.62 | 2,650 | $12,243.00 | 110,049 | SEC Form 4 |
| Segal Lloyd Mitchell | RPTX | PRESIDENT AND CEO | Mar 28 '24 | Sell | $4.63 | 2,491 | $11,533.33 | 107,558 | SEC Form 4 |
| Zinda Michael | RPTX | EVP, CHIEF SCIENTIFIC OFFICER | Mar 28 '24 | Sell | $4.64 | 450 | $2,088.00 | 72,318 | SEC Form 4 |
| Zinda Michael | RPTX | EVP, CHIEF SCIENTIFIC OFFICER | Mar 28 '24 | Sell | $4.66 | 410 | $1,910.60 | 71,908 | SEC Form 4 |
| Koehler Maria | RPTX | EVP, CHIEF MEDICAL OFFICER | Mar 28 '24 | Sell | $4.64 | 500 | $2,320.00 | 231,709 | SEC Form 4 |
| Koehler Maria | RPTX | EVP, CHIEF MEDICAL OFFICER | Mar 28 '24 | Sell | $4.66 | 300 | $1,398.00 | 231,409 | SEC Form 4 |
| Forte Steve | RPTX | EVP, CHIEF FINANCIAL OFFICER | Mar 25 '24 | Sell | $4.79 | 825 | $3,951.75 | 43,862 | SEC Form 4 |
| Forte Steve | RPTX | EVP, CHIEF FINANCIAL OFFICER | Mar 25 '24 | Sell | $4.60 | 825 | $3,795.00 | 43,037 | SEC Form 4 |
| Forte Steve | RPTX | EVP, CHIEF FINANCIAL OFFICER | Mar 25 '24 | Sell | $4.62 | 825 | $3,811.50 | 42,212 | SEC Form 4 |
| Koehler Maria | RPTX | EVP, CHIEF MEDICAL OFFICER | Mar 25 '24 | Sell | $4.78 | 500 | $2,390.00 | 233,209 | SEC Form 4 |
| Koehler Maria | RPTX | EVP, CHIEF MEDICAL OFFICER | Mar 25 '24 | Sell | $4.60 | 500 | $2,300.00 | 232,709 | SEC Form 4 |
| Koehler Maria | RPTX | EVP, CHIEF MEDICAL OFFICER | Mar 25 '24 | Sell | $4.62 | 500 | $2,310.00 | 232,209 | SEC Form 4 |
| Zinda Michael | RPTX | EVP, CHIEF SCIENTIFIC OFFICER | Mar 25 '24 | Sell | $4.78 | 450 | $2,151.00 | 73,668 | SEC Form 4 |
| Zinda Michael | RPTX | EVP, CHIEF SCIENTIFIC OFFICER | Mar 25 '24 | Sell | $4.61 | 450 | $2,074.50 | 73,218 | SEC Form 4 |
| Zinda Michael | RPTX | EVP, CHIEF SCIENTIFIC OFFICER | Mar 25 '24 | Sell | $4.62 | 450 | $2,079.00 | 72,768 | SEC Form 4 |
| Segal Lloyd Mitchell | RPTX | PRESIDENT AND CEO | Mar 25 '24 | Sell | $4.79 | 2,650 | $12,693.50 | 89,166 | SEC Form 4 |
| Segal Lloyd Mitchell | RPTX | PRESIDENT AND CEO | Mar 25 '24 | Sell | $4.64 | 2,650 | $12,296.00 | 86,516 | SEC Form 4 |
| Segal Lloyd Mitchell | RPTX | PRESIDENT AND CEO | Mar 25 '24 | Sell | $4.63 | 2,650 | $12,269.50 | 83,866 | SEC Form 4 |
| BVF PARTNERS L P/IL | RPTX | 10% Owner | Nov 15 '23 | Buy | $5.00 | 493,337 | $2,466,635.67 | 5,155,739 | SEC Form 4 |
| BVF PARTNERS L P/IL | RPTX | 10% Owner | Nov 15 '23 | Buy | $5.00 | 390,507 | $1,952,495.95 | 4,182,664 | SEC Form 4 |
| BVF PARTNERS L P/IL | RPTX | 10% Owner | Nov 15 '23 | Buy | $5.00 | 47,712 | $238,555.23 | 532,795 | SEC Form 4 |
| BVF PARTNERS L P/IL | RPTX | 10% Owner | Nov 15 '23 | Buy | $5.38 | 153,693 | $827,437.00 | 5,309,432 | SEC Form 4 |
| BVF PARTNERS L P/IL | RPTX | 10% Owner | Nov 15 '23 | Buy | $5.38 | 125,909 | $677,856.28 | 4,308,573 | SEC Form 4 |
| BVF PARTNERS L P/IL | RPTX | 10% Owner | Nov 15 '23 | Buy | $5.38 | 16,143 | $86,909.07 | 548,938 | SEC Form 4 |
Latest Repare Therapeutics Inc. News
RPTX Breaking Stock News: Dive into RPTX Ticker-Specific Updates for Smart Investing
MT Newswires
12 days ago
Repare Therapeutics Says Lunresertib With Folfiri Shows 'Promising' Efficacy, Tolerability in Phase 1 Solid Tumor Study
Business Wire
12 days ago
Repare Therapeutics Announces Positive Initial Data at ESMO GI from Phase 1 MINOTAUR Trial Evaluating Lunresertib in Combination with FOLFIRI
MT Newswires
a month ago
Repare Therapeutics Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung Cancer Expansion Trial
Business Wire
a month ago
Repare Therapeutics Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung Cancer Expansion of TRESR Clinical Trial
Business Wire
a month ago
Net Asset Value(s)
GlobeNewswire
a month ago
GPRC5D Targeting Drugs Market Opportunity and Clinical Trials Insight 2024: Insight on 15+ Drugs in Clinical Trials
![[Latest] Global Virtual Reality In Gaming Market Size/Share Worth USD 103,244.7 Million by 2033 at a 16.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)](https://cdn.finquota.com/news/d2b23b51-5b8a-44a4-96fe-60998816c6db.png)
GlobeNewswire
a month ago
[Latest] Global Virtual Reality In Gaming Market Size/Share Worth USD 103,244.7 Million by 2033 at a 16.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
Business Wire
a month ago
CCF Group Successful €225m AT1 Issuance
Share on Social Networks:
Disclaimer
The information presented on this page, "RPTX Repare Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.